Health Trials

Clinical trials

11

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Participants needed: 440
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Aug 18, 2026Locations: 141
Eligibility criteria

Participants must have relapsed or refractory multiple myeloma (RRMM). [+5]

Participants must not have known active or history of central nervous system (CN... [+3]

Read more
Status: Not yet recruiting

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

Participants needed: 92
Trial details
Phase: Phase 3Age: 16+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Aug 3, 2026Locations: 56
Eligibility criteria

Participants must not have a requirement for supplemental oxygen therapy and/or... [+5]

Read more
Status: Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

Participants needed: 65
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Jul 29, 2026Locations: 40
Eligibility criteria

Participant must be 18 years or older at the time of signing the informed consen... [+7]

Participant has a diagnosis of secondary CNS lymphoma due to systemic disease. [+9]

Read more
Status: Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Participants needed: 187
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Jul 16, 2026Locations: 19
Eligibility criteria

History of relapsed and/or refractory multiple myeloma (RRMM) treated with at le... [+3]

Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide... [+2]

Read more
Status: Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.

Participants needed: 125
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Jul 14, 2026Locations: 28
Eligibility criteria

SLE population:. [+4]

Read more
Status: Not yet recruiting

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).

Participants needed: 52
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Jul 9, 2026Locations: 8
Eligibility criteria

Documented clinical diagnosis of chronic ITP (cITP) without other clinical manif... [+4]

ITP or AIHA associated with: Evans syndrome, other systemic autoimmune disease o... [+3]

Read more
Status: Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Participants needed: 230
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: May 28, 2026Locations: 52
Eligibility criteria

Documented diagnosis of multiple myeloma (MM) as per International Myeloma Worki... [+4]

Active or history of central nervous system involvement with MM. [+3]

Read more
Status: Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Participants needed: 187
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Mar 18, 2026Locations: 19
Eligibility criteria

Participants must have a diagnosis of multiple myeloma with relapsed and/or refr... [+4]

Participants must not have any known active or history of central nervous system... [+3]

Read more
Status: Recruiting

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Feb 24, 2025Locations: 1
Eligibility criteria

Participants known to be participating in investigational studies at the time of... [+2]

Read more
Status: Recruiting

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Feb 24, 2025Locations: 1
Eligibility criteria

Participants known to be participating in investigational studies at the time of... [+1]

Read more
Status: Recruiting

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyUpdated: Feb 24, 2025Locations: 1
Eligibility criteria

Participants known to be participating in investigational studies at the time of... [+1]

Read more